(Q34722677)

English

In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas (English)

1 reference

Europe PubMed Central

4 August 2017

author name string

Ken B Waites

1

1 reference

Europe PubMed Central

4 August 2017

Donna M Crabb

2

1 reference

Europe PubMed Central

4 August 2017

Xue Bing

3

1 reference

Europe PubMed Central

4 August 2017

Lynn B Duffy

4

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

4 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

4 August 2017

47

1 reference

Europe PubMed Central

4 August 2017

1

1 reference

Europe PubMed Central

4 August 2017

161-165

1 reference

Europe PubMed Central

4 August 2017

In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

Antipneumococcal activity of BMS 284756 compared to those of six other agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

Comparative in-vitro activity of sparfloxacin against genital pathogens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

7 July 2018

In vitro susceptibility study of BMS-284756 against Legionella species

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=149005

26 October 2018

In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas

1 reference

https://pubmed.ncbi.nlm.nih.gov/12499185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/12499185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas

1 reference

https://pubmed.ncbi.nlm.nih.gov/12499185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12499185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp

1 reference

https://pubmed.ncbi.nlm.nih.gov/12499185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.47.1.161-165.2003

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34722677&oldid=1392192542"